Takeda - takeda.com - Takeda Pharmaceutical Company Limited
General Information:
Latest News:
Takeda Announces Appointment of New Senior Leadership 27 Aug 2013 | 06:00 am
News Release
Takeda and Zinfandel Pharmaceuticals Initiate Phase 3 TOMMORROW Trial of AD-4833 for the Delay of Onset of Mild Cognitive Impairment Due to Alzheimer'... 27 Aug 2013 | 04:00 am
News Release
Takeda Announces Appointment of Chief Financial OfficerNew Position Integrates Global Finance Functions 27 Aug 2013 | 04:00 am
News Release
Data Published in the New England Journal of Medicine for Vedolizumab, an Investigational New Drug from Takeda for Moderately to Severely Active Ulcer... 22 Aug 2013 | 04:00 am
Osaka, Japan – August 21, 2013 – Takeda Pharmaceutical Company Limited (“Takeda”) today announced that results from two Phase 3 studies evaluating vedolizumab, an investigational humanized monoclonal ...
DSP and Takeda Announce Approval of the Marketing Authorization Application for Atypical Antipsychotic Agent Lurasidone in Switzerland 13 Aug 2013 | 04:00 am
News release
Transfer of Business of Takeda Bio Development Center to its Parent Company 1 Aug 2013 | 12:00 pm
News Release
Takeda Announces Appointment of New Senior Leadership 31 Jul 2013 | 11:00 am
News Release
Agreement with Taisho for Distribution of Products of Biofermin and Transfer of a Part of Shares of Biofermin held by Takeda to Taisho 31 Jul 2013 | 11:00 am
Osaka, Japan, July 31, 2013 — Takeda Pharmaceutical Company Limited (“Takeda”) announced today that Takeda and Taisho Pharmaceutical Co., Ltd.* (Headquarters: Tokyo, Japan, “Taisho”) have agreed that ...
Takeda Receives Marketing Authorization from China's CFDA for New Type 2 Diabetes Therapy NESINA (alogliptin) 31 Jul 2013 | 11:00 am
Osaka, Japan, and Shanghai, China, July 31, 2013 – Takeda Pharmaceutical Company Limited (TSE: 4502, “Takeda”) and its wholly-owned subsidiary, Takeda (China) Holdings Co., Ltd. today announced that t...
NOVEL ORAL RHEUMATOID ARTHRITIS TREATMENT JAK INHIBITOR XELJANZ® LAUNCHED IN JAPAN 30 Jul 2013 | 06:00 am
Pfizer Japan Inc. (Head Office: Shibuya-ku, Tokyo; “Pfizer”) and Takeda Pharmaceutical Company Limited (Head Office: Chuo-ku, Osaka; “Takeda”) announced today that the both parties have launched XELJA...
